Background
==========

Enteroviruses belong to the *Picornaviridae* family and are among the most commonly identified aetiological agents of human disease \[[@B1]\]. There are approximately 100 enterovirus serotypes which cause a range of clinical manifestations; from asymptomatic infections to more serious illnesses such as aseptic meningitis, myocarditis and acute flaccid paralysis \[[@B1],[@B2]\]. Enterovirus 68 (EV68) is a member of the Human enterovirus D species and was first isolated in California, USA in 1962 from children who were hospitalised with lower respiratory tract infections \[[@B3]\]. Since then, EV68 has been isolated rarely; only 26 strains have been identified over 36 years in the USA \[[@B2]\]. EV68 is unique among enteroviruses in that it has a lower than optimum growth temperature and is acid sensitive \[[@B4]-[@B6]\]. As such, it shares characteristics with human rhinovirus \[[@B4],[@B5]\]. It is further unique in that it is almost exclusively associated with respiratory disease \[[@B4],[@B5]\]. Recently EV68 has been isolated with increased frequency. Its isolation has been reported in Germany, the Philippines, Thailand, Italy, Japan, the United States, the United Kingdom and the Netherlands with the majority of these reports occurring in 2010 \[[@B7]-[@B15]\]. To date, only four full genome sequences of EV68 have been published; that of the prototype Fermon strain, the French 37--99 strain and two EV68 strains that were circulating in Japan in 2010 \[[@B5],[@B9],[@B16]\].

Objectives
==========

In the current study we describe fifteen cases of EV68 isolated from samples taken from March to August 2010 in New Zealand. All cases were initially identified by partial VP1 sequencing. Due to limiting sample volumes complete VP1 sequencing was performed on only ten of the fifteen EV68 samples confirming EV68 infection. Additionally, characterisation of the full genome sequence of a representative New Zealand EV68 isolate was achieved by Roche 454 sequencing.

Study design
============

Patients and specimen collection
--------------------------------

The National Poliovirus and Enterovirus Identification Reference Laboratory at the Institute of Environmental Science and Research Limited, National Centre for Biosecurity and Infectious Disease routinely receives untyped enterovirus clinical specimens or cell culture isolates from four major hospitals (based in Auckland, Waikato, Wellington and Christchurch) as part of the New Zealand enterovirus surveillance network.

Viruses and cells
-----------------

Human rhabdomyosarcoma (RD) cells (passage 242--256) were propagated in 10% Hanks Minimal Essential Medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% (v/v) foetal bovine serum (HyClone, New Zealand), 7.5% (v/v) sodium bicarbonate, 1% (v/v) 1 M hepes and antibiotics.

RNA extractions
---------------

Viral nucleic acid was extracted (400 μL of clinical specimen or cell culture isolate) using the Zymo ZR Viral RNA Kit™ (Zymo Research Corporation, Irvine, CA, USA) as per the manufacturer's instructions. Nucleic acid extracts (20 μL) were stored at −80°C until required.

Partial and full VP1 RT-PCR and sequencing
------------------------------------------

Initially, specimens were characterised by amplification and sequencing of a 375 bp partial VP1 region as described previously \[[@B17]\]. An EV68 RT-PCR assay was designed in-house using Primer3 v 0.4.0 \[[@B18]\] in order to specifically amplify and sequence the entire VP1 region. The forward primer was designated EV68-VP1-Forward (5'-GCA-GCC-TAT-CAG-GTG-GAG-AG-3') and the reverse primer was designated EV68-VP1-Reverse (5'-TGC- TCA-TGT-ATG-GCA-TGG-TT-3') resulting in a product that was 805 bp in length. One-step RT-PCR assays were performed using the SuperScript III Platinum One-Step System (Invitrogen, Life Technologies). Each 50 μL reaction contained 5 μL of RNA, 25 μL of 2X Reaction Mix, 0.5 μL of reverse transcriptase-*Taq* polymerase enzyme mix, 20 units of RNase inhibitor(Invitrogen) and 0.2 μM of primers. Following an initial 50 minute reverse transcription at 50°C and 15 minute denaturation step at 94°C, a three-step cycling procedure of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and extension at 72°C for 1 minute over 40 cycles was used. A final extension was performed at 72°C for 5 minutes. Each assay included negative and positive extraction controls and RNase-free reagents and procedures were used to minimise contamination.

Samples were run on an E-Gel® EX 2% precast agarose gel (Invitrogen). Bands of interest were purified using the Qiagen QIAquick PCR Purification Kit (Qiagen Incorporated, Valencia, CA, USA) and used as templates for sequencing on an ABI 3130XL automated DNA sequence using ABI Big Dye v3.1 technology (Applied Biosystems, Life Technologies).

Phylogenetic analysis
---------------------

Sequences were edited and assembled using Bionumerics 5.10 (Applied Maths, Belgium) and compared to known VP1 sequences in GenBank using BLAST \[[@B19]\]. Samples were determined to be EV68 strains if they were ≥ 75% similar to the prototype EV68 Fermon strain (GenBank accession number: AY426531).

The phylogenetic relationships were inferred using the Neighbour-Joining method (Tamura 3-parameter model with gamma distributed rates among sites) on nucleotide sequence data from the VP1 region, incorporating 651 base pairs. All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA5 \[[@B20]\] (Center for Evolutionary Medicine and Informatics, Tempe, AZ, USA). 1000 bootstrap replicates were performed to determine the consensus tree.

Enterovirus genome sequencing
-----------------------------

Full-length genomic sequence of EV68 was obtained by sequencing on a Roche GS FLX instrument. Passage 1 viral culture was firstly purified to enrich for virus particles. A 1 mL volume of viral culture was subjected to three cycles of freeze-thaw lysis between −80°C and 37°C and then to centrifugation at 3000 × *g* for 15 minutes. To remove cellular RNA, 400 μL of supernatant was treated with RNAse A (Ambion, Life Technologies) at a final concentration of 10 μg.mL ^-1^ at 37°C for one hour. RNA was extracted from this fraction using the Ambion MagMax Viral RNA kit (Ambion) with elution into 40 μL of EB buffer. The RNA concentration was not high enough for direct application to the Roche GS FLX sequencer so a random amplification method for low yield samples was used, as has been described previously \[[@B21]\]. 500 ng of this material was used to make a barcoded, GS FLX Rapid library (Roche, Mannheim, Germany) according to the manufacturer's instructions except that the sample was not nebulized. Completed library length was between 500 bp and 900 bp and the concentration was 8.35 × 10^9^ molecules/μL. Two emulsion PCR reactions were performed using a library concentration of 4 counts per bead and the enriched beads combined to give a total of 137,200. These were loaded onto a 1/16th region of a pico titre plate and sequenced using the XLR70 Titanium chemistry (Roche). The utilities sffinfo \[[@B22]\] and FASTX-Toolkit \[[@B23]\] were used to remove adaptor and primer sequences and reads filtered based upon data quality. This also increased BLAST search performance because redundant sequence information was not submitted. Human EV68 sequence was assembled using a reference strain, Fermon (GenBank accession number: AY426531). Assembly and annotation was achieved using Geneious 5.5.6 (Biomatters Ltd., New Zealand), on enterovirus hits obtained from the BLASTN search. Areas of assembly with less than 5X coverage were resequenced by the sanger-sequencing methodology using custom designed PCR primers.

Results
=======

Patients and clinical data
--------------------------

In 2010, EV68 was detected in a total of fifteen samples. EV68 positive patients ranged in age from 1 month to 48 years, median age 11 years and 0 months. The majority of patients (*n* = 11; 73.3%) were less than 2 years of age. Patients testing positive for EV68 were predominantly male (*n* = 10; 66.7%) and most were identified as being of Pacific Island or Maori descent (*n* = 12; 80.0%) (Table [1](#T1){ref-type="table"}). The first EV68 positive sample was taken in March of 2010. The peak incidence was observed in June of 2010 (*n* = 7; 46.7%) and this coincides with the winter period in New Zealand, typical of respiratory disease. Most of the samples originated in the Auckland region (n = 13; 86.7%) with the remaining two samples coming from the Waikato region. Respiratory samples included throat swabs (*n* = 1; 6.7%), nasopharyngeal swabs (NPS) (*n* = 4; 26.7%), nasopharyngeal aspirates (NPA) (*n* = 9; 60.0%) and a tracheal aspirate (*n* = 1; 6.7%). Patients presented with bronchiolitis (*n* = 6; 40.0%), asthma (*n* = 2; 13.3%) or other symptoms including cough, stridor, coryza and wheezing (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of fifteen patients in whom enterovirus 68 was isolated in New Zealand in 2010

   **Patient**   **Accession number**   **VP1 sequence**   **Strain name**   **Age**   **Sex**     **Ethnicity**     **Sample taken**    **Sample type**    **Health district**    **Clinical details**
  ------------- ---------------------- ------------------ ----------------- --------- --------- ------------------- ------------------ ------------------- --------------------- ------------------------
        1              JQ13905              Partial          NZ-2010-183       5 m        M            Maori              March               Nasal               Waikato             Bronchiolitis
        2              JQ13906              Partial          NZ-2010-358      14 m        M            Maori               May          Tracheal Aspirate        Auckland                 Burns
        3              JQ13907              Partial          NZ-2010-404       6 m        M            Other               May                 NPA               Auckland             Bronchiolitis
        4              JQ13908              Partial          NZ-2010-431      18 m        F            Other               June                NPA               Auckland         Cough, Stridor, Wheeze
        5              JQ13909              Partial          NZ-2010-435       5 m        M       Pacific Island           June                NPA               Auckland             Cough, Coryza
        6                n/a                   No            NZ-2010-475      15 m        M            Maori               June                NPA               Auckland         Cough, Coryza, Wheeze
        7              JQ13910              Partial          NZ-2010-481      26 y        F       Pacific Island           June                NPS               Auckland               Pertussis
        8              JQ13911              Partial          NZ-2010-539      12 m        M       Pacific Island           June                NPA               Auckland             Severe asthma
        9              JQ13912              Complete         NZ-2010-541       7 m        M       Pacific Island           June                NPA               Auckland             Bronchiolitis
       10              JQ13913              Partial          NZ-2010-571       1 m        M       Pacific Island           June                NPA               Auckland             Cough, Coryza
       11                n/a                   No            NZ-2010-580      46 y        F            Maori               July                NPS               Auckland         Sepsis, Heart Failure
       12                n/a                   No            NZ-2010-594       2 m        M       Pacific Island           July                NPA               Auckland             Bronchiolitis
       13                n/a                   No            NZ-2010-734      38 y        F            Maori               July                NPS               Auckland                 Asthma
       14                n/a                   No           NZ-2010-1058       4 m        M      Cook Island Maori        August               NPA               Auckland             Bronchiolitis
       15              JQ13904              Partial         NZ-2010-1507      48 y        F           Unknown             August             Throat               Waikato             Bronchiolitis

*m* = months; y = years; *M* = male; *F* = female; *NPA* = nasopharyngeal aspirate; *NPS* = nasopharyngeal swab.

VP1 Phylogenetic analysis
-------------------------

Based upon sequencing of the VP1 gene segment of ten New Zealand clinical isolates, the viruses grouped in one distinct phylogenetic cluster (Figure [1](#F1){ref-type="fig"}). Enteroviruses were judged to be the same serotype if they were ≥ 75% similar to the prototype Fermon strain (GenBank accession number: AY426531) but had \< 70% sequence similarity to any other reference strain \[[@B17]\]. The ten New Zealand EV68 isolates had an average of 88.6% similarity to the VP1 of the prototype Fermon strain and only 66.5-68.8% similarity to that of enterovirus 70 (GenBank accession number: DQ201177) and 94 (GenBank accession number: DQ916376) (other species D enteroviruses), thus confirming these viruses as EV68. The New Zealand isolates were 98.0-99.5% identical to each other. The New Zealand EV68 VP1 nucleotide sequences were compared with the sequences of EV68 from the Philippines, Japan and the Netherlands. The VP1 phylogenetic tree demonstrated that the New Zealand EV68 isolates clustered most closely with EV68 isolates that were detected in the Netherlands in 2010 but were not sufficiently distinct from any other EV68 sequence so as to identify them as a genetically distinct group.

![**The evolutionary history was inferred using the Neighbour-Joining method (Tamura 3-parameter model with gamma distributed rates among sites) on nucleotide sequence data from the VP1 region, incorporating 651 base pairs.** All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA5^20^ (Center for Evolutionary Medicine and Informatics, Tempe, AZ, USA). 1000 bootstrap replicates were performed to determine the consensus tree presented in this figure, support for nodes present in greater than 75% of the trees are annotated. The viruses detected in this study are marked with an asterisk. The GenBank accession number and the strain designation is shown for each virus.](1743-422X-10-103-1){#F1}

Enterovirus whole genome sequencing
-----------------------------------

We describe the fifth published complete genome of an EV68 virus with the exception of 32 nucleotides in the 5' UTR which could not be determined either by high throughput or sanger sequencing. The Fermon (GenBank accession number: AY426531), 37--99 (GenBank accession number: EF107098) and two Japanese strains (GenBank accession numbers: AB601882 and AB601883) are the only EV68 strains for which complete genome sequences are available. High-throughput sequencing of NZ-2010-541 (passage 1, viral culture) on 1/16th of a Roche GS FLX Titanium plate produced 41,349 pass filter reads. 40,091 reads were identified as human enterovirus by a BLASTN search of the GenBank non-redundant nucleotide database. 26,523 high quality reads were used to assemble a genome sequence for NZ-2010-541 of 7,320 bp (GenBank accession number: JX070222). The closest complete genome sequence identified was that of the strain 37--99 (GenBank accession number: EF107098) which showed 93.40% nucleotide sequence identity overall (Table [2](#T2){ref-type="table"}). The genome sequence of NZ-2010-541 is unremarkable when compared to the other published genomes and no evidence for recombination was revealed.

###### 

Pairwise comparison of nucleotide sequence identities of NZ-2010-541 with other EV68 strains (shown in %)

   **Strain**   **Accession number**   **Genome**   **5**^**′**^**UTR**   **P1**   **P2**   **P3**   **3**^**′**^**UTR**
  ------------ ---------------------- ------------ --------------------- -------- -------- -------- ---------------------
   JPOC10-378         AB601883            91.3             92.9            90.9     91.0     91.3           98.5
     Fermon           AY426531            88.5             90.2            87.8     88.7     87.9           95.5
     37-99            EF107098            93.4             93.0            93.2     93.4     93.4           100.0

Alignment was performed using the ClustalW algorithim in MEGA, with pairwise distance calculations based upon ungapped regions of the alignment.

*5' UTR* = 5' untranslated region; *P1* = precursor P1; *P2* = precursor P2; *P3* = precursor P3.

Discussion
==========

We have reported an emergence of EV68 infections in New Zealand in 2010. EV68 was detected in a total of fifteen specimens between March and August 2010. We also describe a full length genome sequence of a representative EV68 isolate, which contributes to the four published full genome sequences of EV68; that of the prototype Fermon, that of the French 37-99 strain and two EV68 strains that were circulating in Japan in 2010 \[[@B5],[@B9],[@B16]\]. Until recently, EV68 was only isolated rarely \[[@B2]\]. However in the past couple of years EV68 has been isolated with increased frequency with its isolation being reported in various countries worldwide beginning in 2009 \[[@B7]-[@B13]\]. The isolation of enterovirus 68 in New Zealand in 2010 is consistent with this trend. EV68 is thought to be associated with more severe lower respiratory tract infections such as bronchiolitis and pneumonia as well as causing exacerbations of asthma \[[@B5]\]. New Zealand EV68 patients primarily presented with bronchiolitis, cough, coryza, wheezing and the exacerbation of asthma. Eight patients were admitted to hospital although two of those patients had underlying illness. The high number of EV68 hospitalisations within a short period of time suggests that EV68 could be highly transmissible in the community and capable of causing more severe disease particularly in young children.

The majority (80.0%) of EV68 strains identified in 2010 in New Zealand were from patients of Pacific Island or Maori descent. Of note was that the other 20.0% of cases specified their ethnicity as other suggesting ethnicity other than New Zealand European, Maori, Pacific Island or Asian. Despite the over-representation of theses ethnicities being disproportionately affected by EV68 this dataset is not large enough to conclude EV68 infection is more likely to affect New Zealand Pacific Island and Maori populations but does warrant enhanced surveillance or further study.

An alternative explanation for this is the bias of hospital users, as Pacific Island or Maori ethnic groups are usually over-represented in hospital admissions for acute respiratory tract infections \[[@B24]-[@B27]\]. A number of factors such as nutrition and living conditions, exposure to cigarette smoke and lack of early medical care due to cost may lead to the higher hospitalisation rates among these communities \[[@B24],[@B26],[@B27]\]. New Zealand minority groups are not alone in experiencing higher hospitalisation rates. Internationally, minority groups show higher hospital admission rates for respiratory infections than those in the majority culture \[[@B28]-[@B30]\]. Phylogenetic analysis of the variable VP1 region of the New Zealand EV68 isolates showed that our clinical isolates grouped in one distinct phylogenetic cluster. Comparing the New Zealand EV68 VP1 nucleotide sequences with those from the Philippines, Japan and the Netherlands showed that the New Zealand isolates clustered with EV68 isolates that were detected in the Netherlands in 2010. EV68 isolates from the Netherlands clustered into two distinct phylogenetic groups; those detected in 2009 that were circulating in the community and those detected in 2010 from EV68 positive patients that required hospitalisation \[[@B12]\]. Additional analysis of the EV68 isolates from the Netherlands demonstrated an amino acid deletion at residue 242 in the VP1 protein in the 2010 cluster compared with the 2009 cluster. This deletion was also observed in the New Zealand isolate NZ-2010-541 that was sequenced in this study \[[@B12]\]. This deletion was common to both New Zealand and Netherland hospitalised patients but not to Netherland patients treated in the community and this could indicate increased virulence leading to more severe infection \[[@B12]\]. Further studies are required to understand the role of this deletion in relation to virulence and disease severity and confirm this hypothesis.

It was expected that a full coverage of the NZ-2010-541 genome was not achieved by high throughput sequencing, despite our anticipation that 40,000 sequence reads with an average read length of approximately 500 base pairs should provide an average coverage of approximately 2700X. We noted 17 gaps in the high throughput sequence data with less than 5X coverage which ranged in size from 3 to 180 bp, and custom sanger sequencing primers were designed to fill these gaps.

In summary, this report describes the occurrence of a rare EV68 infection associated with lower respiratory tract infection in young children in New Zealand. The national poliovirus/enterovirus surveillance system is an essential and effective tool in identifying emerging and re-emerging enterovirus outbreaks and has the potential to inform upon public health interventions. An increased awareness of EV68 may help to detect this virus with greater frequency thus providing valuable information to healthcare providers. Generating useful phylogenetic and epidemiological data may help to reveal the reason for the increased activity of this virus in 2010.
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